Page last updated: 2024-11-05

rose bengal b disodium salt

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Rose bengal B disodium salt is a synthetic dye with a long history of use in various applications, including biological staining, photodynamic therapy, and as a photosensitizer. Its structure consists of a xanthene core substituted with four chlorine atoms and two iodine atoms. The disodium salt form enhances its solubility in aqueous solutions. Rose bengal B disodium salt exhibits strong absorption in the visible region of the electromagnetic spectrum, particularly at wavelengths around 545 nm. This property makes it useful as a biological stain, as it preferentially binds to specific cellular structures and can be visualized under a microscope. In photodynamic therapy, rose bengal B disodium salt acts as a photosensitizer, generating singlet oxygen upon exposure to light. This reactive oxygen species can induce cell death in targeted tissues, making it a promising agent for treating various cancers and other diseases. The compound's unique photochemical properties have also led to its investigation as a potential agent for antimicrobial and antiviral therapies. Research continues to explore the diverse applications of rose bengal B disodium salt, particularly in areas related to its biological and photochemical effects.'

Cross-References

ID SourceID
PubMed CID32343
CHEMBL ID2359093
MeSH IDM0322772

Synonyms (49)

Synonym
disodium 2,3,4,5-tetrachloro-6-(2,4,5,7-tetraiodo-6-oxido-3-oxo-3h-xanthen-9-yl)benzoate
ci acid red 94
rose bengal sodium
disodium 3,4,5,6-tetrachloro-2-(2,4,5,7-tetraiodo-6-oxido-3-oxoxanthen-9-yl)benzoate
rose bengal sodium salt, certified by the biological stain commission
rose bengal sodium salt, dye content >=85 %
NCGC00159508-02
rose bengal, dye content 95 %
rose bengal, certified by the biological stain commission, dye content >=80 %
F0001
R0041
dtxcid702814
tox21_111727
cas-632-69-9
dtxsid4022814 ,
tetrachlorotetraiodofluorescein disodium salt
C20347
AKOS024319604
956575sn5l ,
bengal rose b sodium salt
rose bengal sodium [mart.]
rose bengal extra
rose bengal disodium salt [mi]
sodium tetraiodotetrachlorofluorescein
disodium salt of 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodofluorescein
aka105(1) [inci]
rose bengal sodium [inn]
3',4',5',6'-tetrachloro-2,4,5,7-tetraiodofluorescein disodium salt
japan red 105-1
red no. 105-1
rose bengal sodium [who-dd]
2',4',5',7'-tetraiodo-3,4,5,6-tetrachlorofluorescein disodium salt
spiro(isobenzofuran-1(3h), 9'-(9h)xanthen)-3-one, 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5',7'-tetraiodo-, disodium salt
aka105(1)
rose bengal disodium
AKOS015902615
CHEMBL2359093
4,5,6,7-tetrachloro-2',4',5',7'-tetraiodofluorescein sodium salt
A934800
bdbm50498947
632-69-9 (sodium)
pv-10 sodium
rose bengal, 90%, indicator
UWBXIFCTIZXXLS-UHFFFAOYSA-L
sodium 2,3,4,5-tetrachloro-6-(2,4,5,7-tetraiodo-6-oxido-3-oxo-3h-xanthen-9-yl)benzoate
CS-0440614
SY076590
4,5,6,7-tetrachloro-2',4',5',7'-tetraiodofluorescein disodium
rose bengal sodium (mart.)

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
"Sono-Photodynamic therapy (SPDT) utilizing ultrasound and light has been demonstrated that this novel approach can lower dosage resulting in reduction of the potential side effects caused by sensitizers."( Synthesis and biological characterization of novel rose bengal derivatives with improved amphiphilicity for sono-photodynamic therapy.
Chen, HJ; Huang, JD; Wang, AL; Yeh, CK; Zheng, BY; Zhou, XB, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency14.12540.003245.467312,589.2998AID2517
TDP1 proteinHomo sapiens (human)Potency14.96310.000811.382244.6684AID686978; AID686979
AR proteinHomo sapiens (human)Potency10.39500.000221.22318,912.5098AID743040; AID743042; AID743054
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency10.00000.01237.983543.2770AID1346984
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency10.96670.000214.376460.0339AID720691; AID720719
estrogen nuclear receptor alphaHomo sapiens (human)Potency10.79140.000229.305416,493.5996AID743069; AID743078; AID743079
aryl hydrocarbon receptorHomo sapiens (human)Potency5.84680.000723.06741,258.9301AID743085; AID743122
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency12.58930.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency20.91730.000323.4451159.6830AID743065; AID743067
Cellular tumor antigen p53Homo sapiens (human)Potency31.67040.002319.595674.0614AID651631; AID720552
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Protein translocase subunit SecA 1Staphylococcus aureus subsp. aureus NCTC 8325IC50 (µMol)0.75000.50000.75001.0000AID1261201; AID1261203
Bile salt export pumpHomo sapiens (human)IC50 (µMol)10.00000.11007.190310.0000AID1449628
Protein translocase subunit SecA 2Staphylococcus aureus subsp. aureus NCTC 8325IC50 (µMol)2.00002.00002.00002.0000AID1261202
Vesicular acetylcholine transporterRattus norvegicus (Norway rat)IC50 (µMol)9.70000.01504.85759.7000AID515369
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (146)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (41)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (31)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (90)

Assay IDTitleYearJournalArticle
AID1347157Confirmatory screen GU Rhodamine qHTS for Zika virus inhibitors qHTS2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1261190Bactericidal activity against Methicillin sensitive Staphylococcus aureus ATCC 6538 assessed as CFU reduction at 40 uM for 2 hrs under dark condition2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Evaluation of small molecule SecA inhibitors against methicillin-resistant Staphylococcus aureus.
AID1403826Photodynamic anticancer activity in human HepG2 cells preincubated for 2 hrs followed by light exposure at 27 J/cm2 for 30 mins and subsequent incubation for 24 hrs by MTT assay2018European journal of medicinal chemistry, Feb-10, Volume: 145Synthesis and biological characterization of novel rose bengal derivatives with improved amphiphilicity for sono-photodynamic therapy.
AID1583163Cytotoxicity against human PANC1 cells assessed as reduction in cell viability up to 1 uM incubated for 24 hrs under dark condition by MTT assay2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Rose Bengal-Amphiphilic Peptide Conjugate for Enhanced Photodynamic Therapy of Malignant Melanoma.
AID1304439Antitumor activity against mouse B16-F10-luc2 cells ectopically xenografted in nude mouse assessed as tumor growth at 100 uM pretreated with compound followed by ultrasound irradiation measured on day 4 post dosing relative to control2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Comparing the efficacy of photodynamic and sonodynamic therapy in non-melanoma and melanoma skin cancer.
AID690249Cytotoxicity against CHO cells after 3 hrs followed by photo-irradiation for 30 secs measured 24 hrs post irradiation by MTT assay2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Enhanced ROS production and cell death through combined photo- and sono-activation of conventional photosensitising drugs.
AID1583162Cytotoxicity against human MCF7 cells assessed as reduction in cell viability up to 1 uM incubated for 24 hrs under dark condition by MTT assay2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Rose Bengal-Amphiphilic Peptide Conjugate for Enhanced Photodynamic Therapy of Malignant Melanoma.
AID1304420Induction of ROS generation in EtOH/H2O solution assessed as reduction in DPBF absorbance at 0.5 uM preincubated with compound followed by white light irradiation for 30 mins by UV-visible spectrometric analysis relative to control2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Comparing the efficacy of photodynamic and sonodynamic therapy in non-melanoma and melanoma skin cancer.
AID1304432Cytotoxicity against human HeLa cells assessed as reduction in cell viability at 0.5 uM preincubated for 3 hrs followed by 90 J/cm'-2 ultrasound irradiation for 60 sec measured after 24 hrs by MTT assay relative to control2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Comparing the efficacy of photodynamic and sonodynamic therapy in non-melanoma and melanoma skin cancer.
AID1261202Inhibition of Staphylococcus aureus ATCC 35556 SecA2 expressed in Escherichia coli BL21-gammaDE3 assessed as reduction in intrinsic ATPase activity incubated for 3 hrs measured by malachite green colorimetric method2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Evaluation of small molecule SecA inhibitors against methicillin-resistant Staphylococcus aureus.
AID1261197Bacteriostatic activity against Staphylococcus aureus K2068 overexpressing MepA2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Evaluation of small molecule SecA inhibitors against methicillin-resistant Staphylococcus aureus.
AID1304440Toxicity in nude mouse xenografted ectopically with mouse B16-F10-Luc2 cells assessed as reduction in body weight at 100 uM pretreated with compound followed by ultrasound irradiation measured up to 6 days post dosing relative to control2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Comparing the efficacy of photodynamic and sonodynamic therapy in non-melanoma and melanoma skin cancer.
AID1304436Cytotoxicity against mouse RIF1 cells assessed as reduction in cell viability at 0.5 uM preincubated for 3 hrs followed by ultrsound irradiation through 3.4 to 6.8 mm guinea pig skin barrier by MTT assay2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Comparing the efficacy of photodynamic and sonodynamic therapy in non-melanoma and melanoma skin cancer.
AID1261215Bacteriostatic activity against Staphylococcus aureus Newman after 24 hrs2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Evaluation of small molecule SecA inhibitors against methicillin-resistant Staphylococcus aureus.
AID1403823Toxicity in human HepG2 cells up to 5 uM incubated in dark for 24 hrs by MTT assay2018European journal of medicinal chemistry, Feb-10, Volume: 145Synthesis and biological characterization of novel rose bengal derivatives with improved amphiphilicity for sono-photodynamic therapy.
AID1403828Photodynamic anticancer activity in mouse B16F10 cells preincubated for 2 hrs followed by light exposure at 27 J/cm2 for 30 mins and subsequent incubation for 24 hrs by MTT assay2018European journal of medicinal chemistry, Feb-10, Volume: 145Synthesis and biological characterization of novel rose bengal derivatives with improved amphiphilicity for sono-photodynamic therapy.
AID690248Cytotoxicity against CHO cells after 3 hrs followed by photo/sono-irradiation for 30 secs measured 24 hrs post irradiation by MTT assay2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Enhanced ROS production and cell death through combined photo- and sono-activation of conventional photosensitising drugs.
AID1261212Bacteriostatic activity against Staphylococcus aureus N315 after 24 hrs2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Evaluation of small molecule SecA inhibitors against methicillin-resistant Staphylococcus aureus.
AID515367Inhibition of VGLUT2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Rose Bengal analogs and vesicular glutamate transporters (VGLUTs).
AID1304427Cytotoxicity against human HeLa cells assessed as reduction in cell viability at 0.5 uM preincubated for 3 hrs followed by 11.4 J/cm'-2 white light irradiation for 30 sec measured after 24 hrs by MTT assay relative to control2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Comparing the efficacy of photodynamic and sonodynamic therapy in non-melanoma and melanoma skin cancer.
AID1261214Bacteriostatic activity against Staphylococcus aureus Mu50 after 24 hrs2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Evaluation of small molecule SecA inhibitors against methicillin-resistant Staphylococcus aureus.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1893975Cytotoxicity against ewing sarcoma cells (unknown origin)2021European journal of medicinal chemistry, Jan-15, Volume: 210Xanthenes in Medicinal Chemistry - Synthetic strategies and biological activities.
AID1304437Antitumor activity against mouse B16-F10-luc2 cells ectopically xenografted in nude mouse assessed as tumor growth at 100 uM pretreated with compound followed by white light irradiation measured on day 4 post dosing relative to control2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Comparing the efficacy of photodynamic and sonodynamic therapy in non-melanoma and melanoma skin cancer.
AID680435TP_TRANSPORTER: inhibition of Ouabain uptake (Ouabain: 100 uM, Rose bengal: 100 uM) in Xenopus laevis oocytes1996The Journal of pharmacology and experimental therapeutics, Mar, Volume: 276, Issue:3
Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver.
AID1893982Antiviral activity against influenza virus2021European journal of medicinal chemistry, Jan-15, Volume: 210Xanthenes in Medicinal Chemistry - Synthetic strategies and biological activities.
AID690247Cytotoxicity against CHO cells assessed as cell viability at 100 uM after 3 hrs by MTT assay2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Enhanced ROS production and cell death through combined photo- and sono-activation of conventional photosensitising drugs.
AID1893976Cytotoxicity against neuroblastoma cells (unknown origin)2021European journal of medicinal chemistry, Jan-15, Volume: 210Xanthenes in Medicinal Chemistry - Synthetic strategies and biological activities.
AID1304441Toxicity in nude mouse xenografted ectopically with mouse B16-F10-Luc2 cells assessed as reduction in body weight at 100 uM pretreated with compound followed by white light irradiation measured up to 6 days post dosing relative to control2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Comparing the efficacy of photodynamic and sonodynamic therapy in non-melanoma and melanoma skin cancer.
AID1403824Toxicity in human MCF7 cells up to 5 uM incubated in dark for 24 hrs by MTT assay2018European journal of medicinal chemistry, Feb-10, Volume: 145Synthesis and biological characterization of novel rose bengal derivatives with improved amphiphilicity for sono-photodynamic therapy.
AID515368Inhibition of VMAT in rat synaptic vesicles assessed as [3H]HT uptake pretreated for 30 mins measured after 10 mins by scintillation spectrophotometer analysis2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Rose Bengal analogs and vesicular glutamate transporters (VGLUTs).
AID1261201Inhibition of Staphylococcus aureus ATCC 35556 SecA1 expressed in Escherichia coli BL21-gammaDE3 assessed as reduction in intrinsic ATPase activity incubated for 3 hrs measured by malachite green colorimetric method2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Evaluation of small molecule SecA inhibitors against methicillin-resistant Staphylococcus aureus.
AID1261196Bacteriostatic activity against MepA deficient Staphylococcus aureus K29082015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Evaluation of small molecule SecA inhibitors against methicillin-resistant Staphylococcus aureus.
AID1261208Bacteriostatic activity against Staphylococcus aureus ATCC 6538 after 24 hrs2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Evaluation of small molecule SecA inhibitors against methicillin-resistant Staphylococcus aureus.
AID1583155Antitumor activity against mouse B16-F10-luc2 cells implanted in SCID mouse assessed as tumor volume at 100 uM, iv administered 30 mins prior to 68.4 J cm'-2 light irradiation for 3 mins on day 1, 2, 7, and 9 measured for 12 days relative to control2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Rose Bengal-Amphiphilic Peptide Conjugate for Enhanced Photodynamic Therapy of Malignant Melanoma.
AID1893979Cytotoxicity against normal foreskin fibroblast cells (unknown origin)2021European journal of medicinal chemistry, Jan-15, Volume: 210Xanthenes in Medicinal Chemistry - Synthetic strategies and biological activities.
AID1304428Cytotoxicity against human HeLa cells assessed as reduction in cell viability at 0.5 uM preincubated for 3 hrs followed by 22.8 J/cm'-2 white light irradiation for 60 sec measured after 24 hrs by MTT assay relative to control2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Comparing the efficacy of photodynamic and sonodynamic therapy in non-melanoma and melanoma skin cancer.
AID1261225Bactericidal activity against Methicillin sensitive Staphylococcus aureus ATCC 6538 assessed as CFU reduction at 40 uM for 2 hrs in presence of 15W fluorescent light2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Evaluation of small molecule SecA inhibitors against methicillin-resistant Staphylococcus aureus.
AID690259ROS-generating activity of the photo/sono-irradiated compound assessed as singlet oxygen generation measuring reduction in absorbance at 410 nm at 5 uM by DPBF oxidation method2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Enhanced ROS production and cell death through combined photo- and sono-activation of conventional photosensitising drugs.
AID1304435Cytotoxicity against mouse RIF1 cells assessed as reduction in cell viability at 0.5 uM preincubated for 3 hrs followed by white light irradiation through 3.4 to 6.8 mm guinea pig skin barrier by MTT assay2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Comparing the efficacy of photodynamic and sonodynamic therapy in non-melanoma and melanoma skin cancer.
AID1261204Non-competitive inhibition of Staphylococcus aureus ATCC 35556 SecA1 liposomal ATPase activity in Xenopus laevis oocytes incubated for 3 hrs measured by Lineweaver-Burk plot analysis2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Evaluation of small molecule SecA inhibitors against methicillin-resistant Staphylococcus aureus.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1261195Bacteriostatic activity against Staphylococcus aureus K2361 overexpressing NorA2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Evaluation of small molecule SecA inhibitors against methicillin-resistant Staphylococcus aureus.
AID1403822Drug uptake in mouse B16F10 cells assessed as localization in mitochondria at 5 uM after 1.5 hrs by MitoTracker Green staining-based fluorescence assay2018European journal of medicinal chemistry, Feb-10, Volume: 145Synthesis and biological characterization of novel rose bengal derivatives with improved amphiphilicity for sono-photodynamic therapy.
AID1583157Antitumor activity against mouse B16-F10-luc2 cells implanted in SCID mouse assessed as reduction in tumor growth at 100 uM, iv administered 30 mins prior to 68.4 J cm'-2 light irradiation for 3 mins on day 1, 2, 7, and 9 measured on day 132020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Rose Bengal-Amphiphilic Peptide Conjugate for Enhanced Photodynamic Therapy of Malignant Melanoma.
AID1304412Cytotoxicity against mouse B16-F10-luc2 cells assessed as reduction in cell viability at 0.5 uM preincubated for 3 hrs followed by 11.4 J/cm'-2 white light irradiation for 30 sec measured after 24 hrs by MTT assay relative to control2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Comparing the efficacy of photodynamic and sonodynamic therapy in non-melanoma and melanoma skin cancer.
AID1893978Cytotoxicity against rhabdomyosarcoma cells (unknown origin)2021European journal of medicinal chemistry, Jan-15, Volume: 210Xanthenes in Medicinal Chemistry - Synthetic strategies and biological activities.
AID1304433Cytotoxicity against mouse RIF1 cells assessed as reduction in cell viability at 0.5 uM preincubated for 3 hrs followed by 45 J/cm'-2 ultrasound irradiation for 30 sec measured after 24 hrs by MTT assay relative to control2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Comparing the efficacy of photodynamic and sonodynamic therapy in non-melanoma and melanoma skin cancer.
AID1403827Photodynamic anticancer activity in human MCF7 cells preincubated for 2 hrs followed by light exposure at 27 J/cm2 for 30 mins and subsequent incubation for 24 hrs by MTT assay2018European journal of medicinal chemistry, Feb-10, Volume: 145Synthesis and biological characterization of novel rose bengal derivatives with improved amphiphilicity for sono-photodynamic therapy.
AID1304434Cytotoxicity against mouse RIF1 cells assessed as reduction in cell viability at 0.5 uM preincubated for 3 hrs followed by 90 J/cm'-2 ultrasound irradiation for 60 sec measured after 24 hrs by MTT assay relative to control2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Comparing the efficacy of photodynamic and sonodynamic therapy in non-melanoma and melanoma skin cancer.
AID1893980Cytotoxicity against normal lung fibroblast cells (unknown origin)2021European journal of medicinal chemistry, Jan-15, Volume: 210Xanthenes in Medicinal Chemistry - Synthetic strategies and biological activities.
AID690250Cytotoxicity against CHO cells after 3 hrs followed by sono-irradiation for 30 secs measured 24 hrs post irradiation by MTT assay2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Enhanced ROS production and cell death through combined photo- and sono-activation of conventional photosensitising drugs.
AID1403825Toxicity in mouse B16F10 cells up to 5 uM incubated in dark for 24 hrs by MTT assay2018European journal of medicinal chemistry, Feb-10, Volume: 145Synthesis and biological characterization of novel rose bengal derivatives with improved amphiphilicity for sono-photodynamic therapy.
AID690254Cytotoxicity against CHO cells assessed as cell death at 100 uM after 3 hrs followed by photo-irradiation for 30 secs measured 24 hrs post irradiation by MTT assay2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Enhanced ROS production and cell death through combined photo- and sono-activation of conventional photosensitising drugs.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID690257ROS-generating activity of the photo-irradiated compound assessed as singlet oxygen generation measuring reduction in absorbance at 410 nm at 5 uM by DPBF oxidation method2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Enhanced ROS production and cell death through combined photo- and sono-activation of conventional photosensitising drugs.
AID1583151Induction of ROS generation in ethanol assessed as reduction in DPBF absorbance at 410 nm at 1 uM preincubated for 10 mins followed by 342 J cm'-2 light irradiation for 15 mins and measured at 5 mins interval for 15 mins by spectrometric method2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Rose Bengal-Amphiphilic Peptide Conjugate for Enhanced Photodynamic Therapy of Malignant Melanoma.
AID1261203Inhibition of Staphylococcus aureus ATCC 35556 SecA1 liposomal ion channel activity in Xenopus laevis oocytes incubated for 3 hrs measured by recording ion current for 1 min2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Evaluation of small molecule SecA inhibitors against methicillin-resistant Staphylococcus aureus.
AID1304419Cytotoxicity against mouse B16-F10-luc2 cells assessed as reduction in cell viability at 0.5 uM preincubated for 3 hrs followed by 22.8 J/cm'-2 white light irradiation for 60 sec measured after 24 hrs by MTT assay relative to control2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Comparing the efficacy of photodynamic and sonodynamic therapy in non-melanoma and melanoma skin cancer.
AID1893977Cytotoxicity against osteosarcoma cells (unknown origin)2021European journal of medicinal chemistry, Jan-15, Volume: 210Xanthenes in Medicinal Chemistry - Synthetic strategies and biological activities.
AID1304431Cytotoxicity against human HeLa cells assessed as reduction in cell viability at 0.5 uM preincubated for 3 hrs followed by 45 J/cm'-2 ultrasound irradiation for 30 sec measured after 24 hrs by MTT assay relative to control2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Comparing the efficacy of photodynamic and sonodynamic therapy in non-melanoma and melanoma skin cancer.
AID1403821Drug uptake in human HepG2 cells at 5 uM after 2 hrs by confocal microscopy2018European journal of medicinal chemistry, Feb-10, Volume: 145Synthesis and biological characterization of novel rose bengal derivatives with improved amphiphilicity for sono-photodynamic therapy.
AID1304430Cytotoxicity against mouse RIF1 cells assessed as reduction in cell viability at 0.5 uM preincubated for 3 hrs followed by 22.8 J/cm'-2 white light irradiation for 60 sec measured after 24 hrs by MTT assay relative to control2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Comparing the efficacy of photodynamic and sonodynamic therapy in non-melanoma and melanoma skin cancer.
AID1304421Induction of ROS generation in EtOH/H2O solution assessed as reduction in DPBF absorbance at 0.5 uM preincubated with compound followed by ultrasound irradiation for 30 mins by UV-visible spectrometric analysis relative to control2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Comparing the efficacy of photodynamic and sonodynamic therapy in non-melanoma and melanoma skin cancer.
AID515369Inhibition of VACHT in rat synaptic vesicles assessed as [3H]HT uptake pretreated for 30 mins measured after 10 mins by scintillation spectrophotometer analysis2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Rose Bengal analogs and vesicular glutamate transporters (VGLUTs).
AID515365Inhibition of VGLUT in rat synaptic vesicles assessed as [3H]glutamate uptake pretreated for 30 mins measured after 10 mins by scintillation spectrophotometer analysis2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Rose Bengal analogs and vesicular glutamate transporters (VGLUTs).
AID1261193Bacteriostatic activity against wild type Staphylococcus aureus 8325-42015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Evaluation of small molecule SecA inhibitors against methicillin-resistant Staphylococcus aureus.
AID1261213Bacteriostatic activity against Staphylococcus aureus Mu3 after 24 hrs2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Evaluation of small molecule SecA inhibitors against methicillin-resistant Staphylococcus aureus.
AID1261194Bacteriostatic activity against NorA deficient Staphylococcus aureus K17582015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Evaluation of small molecule SecA inhibitors against methicillin-resistant Staphylococcus aureus.
AID690258ROS-generating activity of the sono-irradiated compound assessed as singlet oxygen generation measuring reduction in absorbance at 410 nm at 5 uM by DPBF oxidation method2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Enhanced ROS production and cell death through combined photo- and sono-activation of conventional photosensitising drugs.
AID1304418Cytotoxicity against mouse B16-F10-luc2 cells assessed as reduction in cell viability at 0.5 uM preincubated for 3 hrs followed by 45 J/cm'-2 ultrasound irradiation for 30 sec measured after 24 hrs by MTT assay relative to control2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Comparing the efficacy of photodynamic and sonodynamic therapy in non-melanoma and melanoma skin cancer.
AID1304429Cytotoxicity against mouse RIF1 cells assessed as reduction in cell viability at 0.5 uM preincubated for 3 hrs followed by 11.4 J/cm'-2 white light irradiation for 30 sec measured after 24 hrs by MTT assay relative to control2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Comparing the efficacy of photodynamic and sonodynamic therapy in non-melanoma and melanoma skin cancer.
AID1893981Cytotoxicity against normal primary bone marrow fibroblast cells (unknown origin)2021European journal of medicinal chemistry, Jan-15, Volume: 210Xanthenes in Medicinal Chemistry - Synthetic strategies and biological activities.
AID1304413Cytotoxicity against mouse B16-F10-luc2 cells assessed as reduction in cell viability at 0.5 uM preincubated for 3 hrs followed by 90 J/cm'-2 ultrasound irradiation for 60 sec measured after 24 hrs by MTT assay relative to control2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Comparing the efficacy of photodynamic and sonodynamic therapy in non-melanoma and melanoma skin cancer.
AID1893984Antiviral activity against Vesicular stomatitis virus2021European journal of medicinal chemistry, Jan-15, Volume: 210Xanthenes in Medicinal Chemistry - Synthetic strategies and biological activities.
AID1403834Drug uptake in mouse B16F10 cells assessed as localization in lysosomes at 5 uM after 1.5 hrs by LysoTracker staining-based fluorescence assay2018European journal of medicinal chemistry, Feb-10, Volume: 145Synthesis and biological characterization of novel rose bengal derivatives with improved amphiphilicity for sono-photodynamic therapy.
AID1583142Photo-activated cytotoxicity against mouse B16-F10-luc2 cells assessed as cell viability at 1 uM preincubated for 3 hrs followed by compound washout and subsequent 22.8 J cm'-2 light irradiation for 60 secs measured after 21 hrs by MTT assay relative to c2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Rose Bengal-Amphiphilic Peptide Conjugate for Enhanced Photodynamic Therapy of Malignant Melanoma.
AID690256Cytotoxicity against CHO cells assessed as cell death at 100 uM after 3 hrs followed by photo/sono-irradiation for 30 secs measured 24 hrs post irradiation by MTT assay2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Enhanced ROS production and cell death through combined photo- and sono-activation of conventional photosensitising drugs.
AID690253Cytotoxicity against CHO cells after 3 hrs by MTT assay2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Enhanced ROS production and cell death through combined photo- and sono-activation of conventional photosensitising drugs.
AID690255Cytotoxicity against CHO cells assessed as cell death at 100 uM after 3 hrs followed by sono-irradiation for 30 secs measured 24 hrs post irradiation by MTT assay2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Enhanced ROS production and cell death through combined photo- and sono-activation of conventional photosensitising drugs.
AID1893983Antiviral activity against Human immunodeficiency virus2021European journal of medicinal chemistry, Jan-15, Volume: 210Xanthenes in Medicinal Chemistry - Synthetic strategies and biological activities.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1304438Antitumor activity against mouse B16-F10-luc2 cells ectopically xenografted in nude mouse assessed as tumor growth at 100 uM pretreated with compound followed by ultrasound irradiation measured up to 6 days post dosing relative to control2016Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13
Comparing the efficacy of photodynamic and sonodynamic therapy in non-melanoma and melanoma skin cancer.
AID1403820Octanol-water partition coefficient, log P of the compound after 10 mins2018European journal of medicinal chemistry, Feb-10, Volume: 145Synthesis and biological characterization of novel rose bengal derivatives with improved amphiphilicity for sono-photodynamic therapy.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (7.69)18.2507
2000's0 (0.00)29.6817
2010's8 (61.54)24.3611
2020's4 (30.77)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.61 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index5.25 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (92.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]